← All trials
NCT06658834
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2024
- Primary completion
- Jun 30, 2025
- Completion date
- Aug 30, 2026
- First posted
- Oct 26, 2024
- Last posted
- Oct 26, 2024
- Enrollment
- 129
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- Qingdao UniversityCollaborator
- Nantong UniversityCollaborator
- Bengbu Medical CollegeCollaborator
- The First People's Hospital of Yunan ProvinceCollaborator
- Dalian Medical UniversityCollaborator
- China Medical UniversityCollaborator
- Weifang People's HospitalCollaborator
- Changzhi Medical CollegeCollaborator
- Kunming Medical UniversityCollaborator
- Guizhou Medical UniversityCollaborator
- Suining Central HospitalCollaborator
- North China University of Science and Technology Affiliated HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.